From bench to clinical trials: the rFIXFc story

BrandeisNOW has a new story about the development of recombinant Factor IX Fc,  a candidate drug for hemophila, currently in Phase III cliniical trials. The story behind the Fc fusion technology started in academic labs including Neil Simister‘s at Brandeis, led to a biotech startup (Syntonix), which was then acquired by Biogen Idec, who are now conducing clinical trials.

For more, see http://www.brandeis.edu/now/2011/june/hemophilia.html

Prodrug activation by Cryptosporidium thymidine kinase

Xin Sun, a Biochemistry grad student from the Hedstrom Lab, discusses her recent paper in J. Biol. Chem.:

I get to say the word “diarrhea” within the first 1-2 sentences of
talking to a stranger about what I work on, and the look I get back is always amusing. We work on developing inhibitors against a human pathogen called Cryptosporidium parvum, a nasty little parasite that causes the aforementioned diarrhea. We specifically zoomed in on the parasite’s nucleotide synthesis pathways to look for potential drug targets. Our recent paper looked at the enyzme thymidine kinase from the parasite, and studied its role in activating a prodrug that we showed to be effective in reducing parasite load in both a cell culture assay,  and in a mouse model.

Protected by Akismet
Blog with WordPress

Welcome Guest | Login (Brandeis Members Only)